As a leading health care provider in southwest Germany the Ulm University Medical Centre offers state-of-the-art medical services to all the people living in the region and beyond. With more than 1,150 beds the medical team at Ulm provide inpatient treatment to about 44,000 patients each year. Furthermore, they treat approximately 60,000 ambulatory patients. In every case they are guided by the latest scientific findings to ensure the best therapies for every patient.
The doctors and scientists are working in 25 departments and 13 institutes. With their internationally accepted research they contribute to improving healthcare. They always pursue to gain a better understanding of human diseases and to improve the treatments for their patients. Moreover, they also combine the medical service and research with teaching in order to train tomorrow’s doctors, medical-technical specialists and caregivers. With more than 6.000 employees the Ulm University Medical Centre is one of the major employers in the region
LUMC is a modern university medical centre for research, education and patient care with a high-quality profile and a strong scientific orientation. Its unique research practice, ranging from pure fundamental medical research to applied clinical research, places LUMC among the world top. This enables LUMC to offer patient care and education that is in line with the latest international insights and standards – and helps it to improve medicine and healthcare both internally and externally.
LUMC acts as a knowledge centre for topics in the field of public health with an impact on society, it has a directive function in the region and it acts as a centre for continuing education and further training for medical professionals
CIBIT/ICNAS (Coimbra Institute for Biomedical Imaging and Translational Research/Institute of Nuclear Sciences Applied to Heath) is a leading institution in multimodal and multi-organ imaging (eye, brain, heart, liver, prostate) which was recently evaluated by an international panel within the scope of the CNC.IBILI consortium. We form an axis of national leadership in medical imaging that prioritises interdisciplinary contributions in the fields of Biomedical Engineering, Medical Devices, Biomarker Discovery, Preclinical Research, Cognitive Neuroscience, Human and Animal Neurophysiology, Functional Brain Imaging and translational research in Neurology, Cardiology and Oncology. Particular technological strengths include MR, OCT, PET imaging, neurophysiology, molecular probe production and molecular imaging (given cyclotron and radio pharmacy facilities). Available resources include Human Brain Imaging (3T Siemens Scanner), High-density EEG/ERP, Simultaneous EEG/fMRI, Electrocorticography, OCT, Human PET Brain Imaging using 11C and 18F compounds, Radiopharmaceutical production, Psychophysiological studies, Data Analysis, Data Archiving, Training in data acquisition and Training in data analysis.
Together with CNC.IBILI, we have been committed to fundamental and translational research and advanced training in biomedical sciences. This consortium was evaluated as “Excellent” in the latest (2013) national assessment and ranked 1st in h-index and citations per FTE researcher, among comparable research institutions in the health sciences domain. It brought together researchers from the Faculties of Medicine, Pharmacy and Science and Technology, as well as clinicians and collaborators from the pharmaceutical industry. Remarkable achievements were made in the study of degenerative processes and associated mechanisms of protection and regeneration, along with the development of innovative therapeutic strategies and the implementation of a diagnostic imaging program for tackling vision and brain disorders.
CIBIT/ICNAS is also a cutting-edge medical imaging centre at European level for pre- and clinical applications and leads the Core Node of the National Brain Imaging Network. We provide a rich environment for translating fundamental research into clinical or marketable applications, given the strategic partnerships with the University Hospitals (CHUC), ICNAS-Produção and the BIOCANT biotechnology park that hosts 40% of the biotech companies in Portugal.
King’s College London is one of the top 25 universities in the world (2016/17 QS World University Rankings) and among the oldest in England. King’s has more than 29,600 students (of whom nearly 11,700 are graduate students) from some 150 countries worldwide, and some 8,000 staff.
King’s has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF), eighty-four per cent of research at King’s was deemed ‘world-leading’ or ‘internationally excellent’ (3* and 4*).
Since our foundation, King’s students and staff have dedicated themselves in the service of society. King’s will continue to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit our website to find out more about Vision 2029, King’s strategic vision for the next 12 years to 2029, which will be the 200th anniversary of the founding of the university.
King’s College Hospital NHS Foundation Trust is one of the UK’s largest and busiest teaching hospitals, training over 900 dentists, 750 doctors and 300 nurses every year. The Trust is recognized internationally for its work in liver disease and transplantation, neurosciences, cardiac, haemato-oncology, stroke and major trauma. On 1 October 2013, King’s took over the running of the Princess Royal University Hospital in Bromley and Orpington Hospital, as well as some services at Beckenham Beacon and Queen Mary’s Hospital, Sidcup. The new enlarged organisation has over 10,500 staff and provides over 1 million patient contacts a year. 9,000 babies are delivered by our hospitals each year, and over 750 patients come to our Emergency Departments every day. For more information, please visit the website. You can also support the work of King’s College Hospital at www.supportkings.org.uk
The Health Economics Research Centre (HERC) was established in 1998 and is part of the Nuffield Department of Population Health (NDPH) within the University of Oxford’s Medical Sciences Division. HERC has contributed substantially to health and healthcare both in the UK and internationally by conducting research on economic aspects of health and disease, the costs and benefits of prevention and treatment, and the design and evaluation of health systems. Members of the HERC research team (Dr Borislava Mihaylova, Dr Joel Smith, Winnie Mei and David Jones) are collaborating with Perspectum Diagnostics on the RADIcAL-1 trial to estimate the cost-effectiveness of LiverMultiScan™ for patients with suspected Non-Alcoholic Fatty Liver Disease (NAFLD).
Perspectum Diagnostics is a medical imaging company with a Corelab compliance with ISO 13485, ISO 9001 and ISO/IEC 27001. The company has developed a novel imaging technology, LiverMultiScan™, which is a non-invasive MRI post-processing tool that has attained CE-marking and FDA clearance as an aid for diagnosis. This technology can play an important role in the diagnosis of liver disease and in the evaluation of patients receiving treatment for liver disease, and can help many patients avoid the need for painful and time-consuming surgical liver biopsies.
Independent Oversight is provided by an International Steering Committee Board. Current membership of this committee are as follows: